WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Postmarket & security

THE TAPE

Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register

The Tracker / November 2025 / P240026

PMA approved

OncoMate® MSI Dx Analysis System

Promega Corporation · Nov 5, 2025 · P240026

FDA approved the OncoMate® MSI Dx Analysis System from Promega Corporation on Nov 5, 2025 under P240026, an original premarket approval. The device falls under product code SFL, Nucleic Acid Based Assay, Microsatellite Instability as a Class 3 device. The review panel was Medical Genetics.

FDA logged the submission as received on Jul 26, 2024. The decision came 467 days later.

This is the only decision on file for Promega Corporation in the last 12 months of the tracker.

Questions & Answers

What did FDA approve under P240026?

P240026 is the FDA PMA for OncoMate® MSI Dx Analysis System, submitted by Promega Corporation. FDA's decision date was Nov 5, 2025, under product code SFL (Nucleic Acid Based Assay, Microsatellite Instability).

Who makes the OncoMate® MSI Dx Analysis System?

Promega Corporation, based in Madison, WI, is the applicant of record for P240026.

How long did the P240026 review take?

FDA received the submission on Jul 26, 2024 and issued its decision on Nov 5, 2025, 467 days later.

← All decisions in November 2025